FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

被引：0
|
作者：
Alberto Zaniboni
Enrico Aitini
Sandro Barni
Daris Ferrari
Stefano Cascinu
Vincenzo Catalano
Giuseppe Valmadre
Domenica Ferrara
Enzo Veltri
Claudio Codignola
Roberto Labianca
机构：
[1] Fondazione Poliambulanza,Medical Oncology Unit
[2] C. Poma Hospital,Medical Oncology Unit
[3] Treviglio-Caravaggio Hospital,Medical Oncology Unit
[4] S. Paolo Hospital,Medical Oncology Unit
[5] Università Politecnica delle Marche,Medical Oncology Unit
[6] Ospedali Riuniti di Ancona,Medical Oncology Unit
[7] Ospedali Riuniti Marche Nord,Medical Oncology DH
[8] Presidio San Salvatore,Medical Oncology Unit
[9] Ospedale di Sondalo,Medical Oncology Unit
[10] Ospedale San Carlo,Department of Surgery
[11] Ospedale Don Luigi di Liegro,Medical Oncology Unit
[12] Fondazione Poliambulanza,undefined
[13] Ospedali Riuniti,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Pancreatic cancer; FOLFIRI; Chemotherapy; Second-line; Irinotecan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1641 / 1645
页数：4
相关论文
共 50 条
  • [1] FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
    Zaniboni, Alberto
    Aitini, Enrico
    Barni, Sandro
    Ferrari, Daris
    Cascinu, Stefano
    Catalano, Vincenzo
    Valmadre, Giuseppe
    Ferrara, Domenica
    Veltri, Enzo
    Codignola, Claudio
    Labianca, Roberto
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1641 - 1645
  • [2] Folfiri as second-line treatment in advanced pancreatic cancer: A phase II study
    Giuliani, F.
    Mallamaci, R.
    Di Bisceglie, M.
    Galetta, D.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII158 - VII158
  • [3] Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer:: a multicenter phase II trial
    Boeck, S.
    Weigang-Koehler, K.
    Fuchs, M.
    Kettner, E.
    Quietzsch, D.
    Trojan, J.
    Stoetzer, O.
    Zeuzem, S.
    Lordick, F.
    Koehne, C. -H.
    Kroening, H.
    Steinmetz, T.
    Depenbrock, H.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2007, 18 (04) : 745 - 751
  • [4] Second-line chemotherapy by FOLFIRI in patients with advanced small bowel adenocarcinoma A multicenter AGEO study
    Zaanan, A.
    Gauthier, M.
    Malka, D.
    Locher, C.
    Gornet, J.
    Thirot-Bidault, A.
    Tougeron, D.
    Taieb, J.
    Bonnetain, F.
    Aparicio, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Role of second-line chemotherapy in advanced pancreatic cancer and its influence on phase II/III study results
    Teo, M.
    McDermott, R. S.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2462 - 2463
  • [6] Second-line chemotherapy by FOLFIRINOX with unresectable pancreatic cancer (phase I, II study)
    Kobayashi, Noritoshi
    Tokuhisa, Motohiko
    Goto, Ayumu
    Endo, Itaru
    Ichikawa, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] SECOND-LINE CHEMOTHERAPY BY FOLFIRINOX WITH UNRESECTABLE PANCREATIC CANCER (PHASE I, II STUDY)
    Kobayashi, N.
    Shimamura, T.
    Tokuhisa, M.
    Goto, A.
    Endo, I.
    Ichikawa, Y.
    ANNALS OF ONCOLOGY, 2013, 24
  • [8] Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: A multicenter phase II study
    Baek, JH
    Kim, JG
    Sohn, SK
    Kim, DH
    Lee, KB
    Song, HS
    Kwon, KY
    Do, YR
    Ryoo, HM
    Bae, SH
    Park, KU
    Kim, MK
    Lee, KH
    Hyun, MS
    Chung, HY
    Yu, W
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2005, 20 (06) : 966 - 970
  • [9] A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy
    Hwang, J. Y.
    Yoo, C.
    Kim, T.
    Lee, J.
    Park, D.
    Seo, D.
    Lee, S.
    Kim, M.
    Han, D.
    Kim, S.
    Lee, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer
    Jivesh J. Sharma
    Betty Razvillas
    C.D. Stephens
    Susan G. Hilsenbeck
    Ashu Sharma
    Mace L. Rothenberg
    Investigational New Drugs, 1997, 15 : 361 - 364
12345